18 stories mentioning IEXUpdated 3d ago
Every FINWIRES story that references IEX, newest first.
IDEX (IEX) has an average rating of overweight and mean price target of $250.15, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $235.18, Change: $+5.66, Percent Change: +2.47%
IDEX (IEX) has an average rating of overweight and mean price target of $250.15, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $235.18, Change: $+5.66, Percent Change: +2.47%
IDEX (IEX) has an average rating of overweight and mean price target of $250.15, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $235.18, Change: $+5.66, Percent Change: +2.47%
IDEX Keeps Quarterly Dividend at $0.73 a Share, Payable July 24 to Shareholders of Record on July 6
Eric D Ashleman, Director, CEO, and President, on May 11, 2026, sold 15,385 shares in Idex (IEX) for $3,311,195. Following the Form 4 filing with the SEC, Ashleman has control over a total of 66,658 common shares of the company, with 66,658 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/832101/000090514826002252/xslF345X05/form4.xml
IDEX Raises Quarterly Dividend to $0.73 a Share From $0.71, Payable June 5 to Shareholders of Record on May 22
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $214.86, Change: $-2.99, Percent Change: -1.37%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $235 from $220 following Q1, valuing shares at 26x our 2027 EPS outlook of $9.04 (up from $8.99; 2026 EPS view revised to $8.50 from $8.28). IEX posted a robust Q1, with operating EPS of $2.00 rising 14% Y/Y and exceeding consensus by $0.23, propelled by standout performance in Health & Science Tech. Organic sales growth accelerated to 5% Y/Y from 1% in Q4, while orders hit a record $988M (up 10% Y/Y), signaling broadened demand. Health & Science Tech was the clear growth engine, delivering 11% organic sales growth alongside 100-bp adjusted EBITDA margin expansion to 26.6%. This strength was fueled by AI-driven demand for data center power solutions, semiconductor applications, and space & defense markets. Despite gross margin compression of 40 bps, adjusted EBITDA margin expanded 50 bps to 26%, suggesting the company's 80/20 initiatives are gaining traction.Overall, Q1 results were encouraging and contributed to our raised growth outlook for the year.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $235 from $220 following Q1, valuing shares at 26x our 2027 EPS outlook of $9.04 (up from $8.99; 2026 EPS view revised to $8.50 from $8.28). IEX posted a robust Q1, with operating EPS of $2.00 rising 14% Y/Y and exceeding consensus by $0.23, propelled by standout performance in Health & Science Tech. Organic sales growth accelerated to 5% Y/Y from 1% in Q4, while orders hit a record $988M (up 10% Y/Y), signaling broadened demand. Health & Science Tech was the clear growth engine, delivering 11% organic sales growth alongside 100-bp adjusted EBITDA margin expansion to 26.6%. This strength was fueled by AI-driven demand for data center power solutions, semiconductor applications, and space & defense markets. Despite gross margin compression of 40 bps, adjusted EBITDA margin expanded 50 bps to 26%, suggesting the company's 80/20 initiatives are gaining traction.Overall, Q1 results were encouraging and contributed to our raised growth outlook for the year.
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $218.37, Change: $+1.03, Percent Change: +0.47%
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $218.37, Change: $+1.03, Percent Change: +0.47%
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $218.48, Change: $+1.14, Percent Change: +0.52%
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $218.35, Change: $+1.01, Percent Change: +0.46%
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $218.35, Change: $+1.01, Percent Change: +0.46%
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $218.35, Change: $+1.01, Percent Change: +0.46%
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $218.56, Change: $+1.22, Percent Change: +0.56%
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $219.82, Change: $+2.47, Percent Change: +1.14%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:IEX's Q1 results significantly exceeded expectations with operating EPS of $2.00 (up 14% Y/Y) vs. consensus of $1.77, representing a solid $0.23 beat, while organic sales growth accelerated to 5% from Q4's 1%. Orders hit a record $988M (up 10%) as demand broadened across the diversified portfolio. The Health & Science Tech segment was the primary growth driver, with 17% reported and 11% organic sales growth, plus 100 bps of adjusted EBITDA margin expansion to 26.6%, underpinned by AI-driven data center power solutions demand and semiconductor applications. Management raised full-year 2026 guidance, projecting organic sales growth of 3%-4% (up from 1%-2%) and adjusted EPS of $8.35-$8.55 (up from $8.15-$8.35). While gross margin declined 40 bps to 44.9% due to unfavorable mix, adjusted EBITDA margin expanded 50 bps to 26%, as 80/20 initiatives bear fruit. In our view, the upgraded outlook reflects an improved demand backdrop across IEX's diversified end markets.
